We are very pleased to see that OPKO Health (OPK) just hit $5 per share in pre-market trading for a gain of 140.38% from our April 23rd suggestion price of $2.08 per share. OPK recently won a major contract to manage COVID-19 testing for the NBA restart and has become the #1 COVID-19 testing play in the entire market!
On the London Stock Exchange this morning there is a stock Synairgen (SNG.L) that is up by 456% because they announced positive results from its clinical trial of SNG001, its inhaled formulation of interferon beta, in hospitalised COVID-19 patients. Synairgen reported this morning that SNG001 produced a 79% lower risk of patients developing severe disease than those given a placebo in initial trials, and patients that received the treatment “were more than twice as likely to recover (defined as ‘no limitation of activities’ or ‘no clinical or virological evidence of infection’) over the course of the treatment period compared to those receiving placebo".
NIA is aware of a small-cap Canadian listed company BetterLife Pharma (CSE: BETR) with a U.S. symbol BETRD that is currently trading for $1.89 per share with a market cap of only US$24.1 million and its wholly owned BLife Therapeutics is planning clinical trials of AP-003 to test the efficacy of IFNa2b for treatment of COVID-19. AP-003 is being developed as a novel interferon alpha2b (IFNa2b) inhalation formulation.
Synairgen's market cap this morning has increased from US$68.87 million up to a current market cap of US$378.72 million and we believe BETR's AP-003 is superior to Synairgen's SNG001!
BETR is in the midst of securing clearance to initiate a Phase II study of AP-003 against COVID-19 this summer. BETR hopes that an inhaler delivering AP-003 directly to a patient’s lungs could make a difference by not only treating those who are seriously ill in the hospital, but by eventually also being used as a coronavirus prophylaxis/prevention, allowing sufferers and those at high risk the ability to treat themselves at home before even becoming ill!
Past performance is not an indicator of future returns. NIA is not an investment advisor and does not provide investment advice. Always do your own research and make your own investment decisions. This message is not a solicitation or recommendation to buy, sell, or hold securities. NIA has received compensation from BETR of USD$50,000 cash for a six-month marketing contract. This message is meant for informational and educational purposes only and does not provide investment advice.